近年来，以程序性死亡受体-1（programmed death‑1，PD‑1）抗体、程序性死亡蛋白-配体 1（programmed death ligand‑1，PD‑L1）抗体和细胞毒性 T 淋巴细胞相关抗原-4（cytotoxic T ...

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

研究首先在真实世界数据集中对SCORPIO进行了全面测试。模型的开发和初步验证基于来自纪念斯隆-凯特琳癌症中心（MSKCC）的近4000名患者的数据，这些患者涵盖了21种癌症类型，并接受了免疫检查点抑制剂（ICIs）治疗。在测试数据集中，SCORPI ...

HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $8.00 price ...

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute's Toni Choueiri, MD, researchers ...

Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market ...

Immune checkpoint blockade is one of the major advances in cancer treatment in recent years. However, the majority of immune ...

D. Boral Capital initiated coverage of Checkpoint Therapeutics (CKPT) with a Buy rating and $9 price target The company’s lead drug, Unloxcty, ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for ...